Targeting BMP and TAZ/TEAD mechanotransduction pathways impairs AML chemoresistance

ABSTRACT: Despite extensive research and intensive use of chemotherapies in clinics, the 5-year overall survival of Acute Myeloid Leukemia (AML) patients does not exceed 20%. The clonal expansion of leukemic blasts leads to modifications of the bone marrow physical properties, including increased extracellular matrix stiffening, upregulation of intramedullary pressure and reduction of the space available for cells. These biomechanical modifications are speculated to alter therapeutic response and cause treatment resistance. This project aims to decipher the role of mechanotransduction pathways in specially the Hippo pathway in resistant AML.

ORGANISM(S): Homo sapiens

PROVIDER: GSE311903 | GEO | 2026/03/03

REPOSITORIES: GEO